Search results
21 sie 2018 · The USPSTF recommends against screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and do not have a history of a high-grade precancerous lesion (ie, cervical intraepithelial neoplasia [CIN] grade 2 or 3) or cervical cancer.
21 sie 2018 · In 2012, the US Preventive Services Task Force (USPSTF) recommended screening women aged 21 to 65 years for cervical cancer with cytology (Papanicolaou [Pap] smear) every 3 years, with an option for women 30 years and older for hrHPV cotesting (cytology and cervical swab for hrHPV) every 5 years (A recommendation).
21 sie 2018 · Screening with cervical cytology alone, primary testing for hrHPV alone, or both at the same time (cotesting) can detect high-grade precancerous cervical lesions and cervical cancer. Clinicians should focus on ensuring that women receive adequate screening, appropriate evaluation of abnormal results, and indicated treatment, regardless of which ...
In 2018, the U.S. Preventive Services Task Force (USPSTF) recommended primary human papillomavirus (HPV) testing without cytology as an option for cervical cancer screening.
Cervical cancer screening looks for signs of cervical cancer before you feel symptoms from the disease. It does not screen for ovarian, uterine, vaginal, or vulvar cancers. Two screening tests can help prevent cervical cancer or find it early: The Pap test (or Pap smear) looks for precancers, cell changes on the cervix that might become ...
The adoption of the USPSTF guidelines expands the recommended options for cervical cancer screening in average-risk individuals aged 30 years and older to include screening every 5 years with primary high-risk human papillomavirus (hrHPV) testing.
Links and resources related to cervical screening, management, and colposcopy guidelines and recommendations. USPSTF Screening Guidelines. ASCCP endorses the United States Preventative Services Task Force (USPSTF) cervical cancer screening guidelines. View Guidelines.
